Benzinga | Aug 12, 2020 07:13AM EDT

Ascendis Pharma A/S Receives Orphan Designation For TransCon CNP For The Treatment Of Achondroplasia In Europe

OPENHAGEN, Denmark, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the European Commission (EC) has granted Orphan Designation to TransCon C-Type Natriuretic Peptide (CNP) for the treatment of achondroplasia, the most common form of dwarfism.1 TransCon CNP is a investigational long-acting prodrug of CNP, designed to provide continuous exposure of CNP at safe, therapeutic levels via a single, weekly subcutaneous dose. TransCon CNP also received orphan designation for the treatment of achondroplasia in the United States (U.S.) in February 2019. Currently, there is no medical therapy approved for the treatment of achondroplasia.2